Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hong Kong Pharma Digital Technology Holdings Ltd. ( (HKPD) ) has issued an announcement.
On March 18, 2026, Cellyan Biotechnology Co., Ltd filed a Form 6-K in the United States to furnish unaudited interim consolidated financial statements for the six months ended September 30, 2025, alongside comparative figures for 2024. The disclosure shows revenue declined to $7.14 million from $11.09 million year-on-year, with net profit dropping to $153,735 from $828,559, signaling weaker top-line performance but continued profitability and providing investors and other stakeholders with updated visibility into the company’s financial position and operations.
More about Hong Kong Pharma Digital Technology Holdings Ltd.
Cellyan Biotechnology Co., Ltd, formerly known as Hong Kong Pharma Digital Technology Holdings Limited, is a Cayman Islands–incorporated biotechnology company operating from Hong Kong. The group focuses on biopharmaceutical-related products and services, with operations reflected through manufacturing, distribution and associated technology-enabled activities across its markets.
Average Trading Volume: 42,066
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.82M
For detailed information about HKPD stock, go to TipRanks’ Stock Analysis page.